Is This a New Reason to Buy Pfizer Stock Hand Over Fist?

Despite Pfizer's (NYSE: PFE) recent struggles with falling earnings and a bid by an activist investor to unseat its leadership, the pharma juggernaut is still actively advancing its core priorities and giving investors plenty of reasons to consider buying its stock while it's cheap.With that in mind, here's one new initiative that's worth thinking about if you're wondering about whether to make an investment.On Nov. 20, Pfizer announced that its strategic partnership with Flagship Pioneering, a highly prestigious biopharma venture capital (VC) group, had agreed on a new collaboration.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool